0000000001296096
AUTHOR
Kamin W
Meningitis bei 154 Kindern einer Kinderklinik in Deutschland: Klinische und epidemiologische Aspekte
In a retrospective study, the histories of the non-neonates treated for primary meningitis in the Pediatric Department of Mainz University Hospital between 1986 and 1989 were analyzed with regard to etiological, diagnostic, clinical and epidemiological criteria. In the period studied there were 37 cases of infectious meningitis (11 Neisseria meningitidis (29.7%), 7 H. influenzae (18.9%), 3 S. pneumoniae (8.1%), 16 other (43.2%)), and 117 cases of acute aseptic meningitis syndrome (12 mumps virus (10.3%), 3 Borrelia burgdorferi (7.7%), 3 FSME (2.6%), 2 herpes simplex virus, 91 other (77.8%)). Sixty-six percent of the patients were male. Of the infants with infectious meningitis, 68% were und…
Diarrhoe bei 1337 Kindern der Universitätsklinik Mainz: Bedeutung von Salmonellen und Rotaviren
In Germany, infectious diseases cause little mortality, but they are responsible for a large proportion of morbidity. In order to obtain data about the relevance of infectious diarrhea, the charts of 1337 outpatients, hospitalized for this disorder in the time between 1986-1989 at the Children's Hospital, Johannes Gutenberg University Mainz, were analyzed. Sixty-seven percent of patients were younger than one year. An offending organism could be isolated in 42.1% of patients, with Rotaviruses being the leading cause of diarrhea (415 cases), followed by Salmonella spp. (130 cases). Rotavirus-disease was mainly seen in winter, Salmonella-disease in late summer and in autumn. Severe courses of…
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
Summary Background The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side-effects. Objective The aim of this study was to study the effect of omalizumab, a monoclonal anti-IgE antibody, in combination with SIT in patients with seasonal allergic rhinoconjunctivitis (SAR) and co-morbid seasonal allergic asthma (SAA) incompletely controlled by conventional pharmacotherapy. Methods A randomized, double-blind, placebo-controlled, multi-centre trial was performed to assess the efficacy and safety of omalizumab (Xolair®) vs. placebo in combination with depigmented SIT (Depigoid®) during the grass pollen season. Omalizumab or placebo was started 2 weeks befor…